Scopia Capital Management LP Trimmed Its Ligand Pharmaceuticals (LGND) Stake; Flippin Bruce & Porter Has Raised Its General Electric (GE) Holding

December 7, 2017 - By Louis Casey

Scopia Capital Management Lp decreased Ligand Pharmaceuticals Inc (LGND) stake by 37.4% reported in 2017Q2 SEC filing. Scopia Capital Management Lp sold 435,269 shares as Ligand Pharmaceuticals Inc (LGND)’s stock rose 7.66%. The Scopia Capital Management Lp holds 728,563 shares with $88.45 million value, down from 1.16 million last quarter. Ligand Pharmaceuticals Inc now has $2.73 billion valuation. The stock increased 0.93% or $1.19 during the last trading session, reaching $129.55. About 111,734 shares traded. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has declined 2.87% since December 7, 2016 and is downtrending. It has underperformed by 19.57% the S&P500.

Flippin Bruce & Porter Inc increased General Electric (GE) stake by 3.42% reported in 2017Q2 SEC filing. Flippin Bruce & Porter Inc acquired 11,611 shares as General Electric (GE)’s stock declined 7.64%. The Flippin Bruce & Porter Inc holds 351,076 shares with $9.48M value, up from 339,465 last quarter. General Electric now has $153.15B valuation. The stock decreased 0.56% or $0.1 during the last trading session, reaching $17.66. About 43.91M shares traded. General Electric Company (NYSE:GE) has declined 4.46% since December 7, 2016 and is downtrending. It has underperformed by 21.16% the S&P500.

Among 6 analysts covering Ligand Pharmaceuticals (NASDAQ:LGND), 5 have Buy rating, 1 Sell and 0 Hold. Therefore 83% are positive. Ligand Pharmaceuticals had 23 analyst reports since September 3, 2015 according to SRatingsIntel. The rating was maintained by Deutsche Bank with “Hold” on Tuesday, August 8. The firm has “Buy” rating by TH Capital given on Wednesday, September 30. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, September 5. Stephens initiated Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) rating on Wednesday, April 13. Stephens has “Overweight” rating and $150 target. The company was maintained on Thursday, November 19 by Roth Capital. The stock has “Buy” rating by Roth Capital on Monday, November 13. The rating was maintained by Roth Capital on Monday, September 21 with “Buy”. The company was maintained on Wednesday, October 18 by H.C. Wainwright. TH Capital maintained it with “Buy” rating and $144 target in Thursday, November 19 report. The firm has “Buy” rating by TH Capital given on Friday, December 18.

Investors sentiment increased to 1.24 in Q2 2017. Its up 0.06, from 1.18 in 2017Q1. It increased, as 22 investors sold LGND shares while 79 reduced holdings. 36 funds opened positions while 89 raised stakes. 22.57 million shares or 0.91% more from 22.37 million shares in 2017Q1 were reported. The Florida-based Raymond James Associate has invested 0% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Parsons Cap Ri owns 3,667 shares or 0.05% of their US portfolio. Tower Research Ltd (Trc) holds 0% or 235 shares. Vanguard Grp owns 1.74 million shares or 0.01% of their US portfolio. Glenmede Trust Na invested in 0% or 744 shares. Redwood Ltd Limited Liability Company holds 70,809 shares or 0.87% of its portfolio. Proshare Advsrs Limited Liability Corp holds 13,271 shares. Jw Asset Mngmt Ltd Liability has 1.04% invested in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) for 13,401 shares. Brown Advisory owns 0% invested in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) for 8,596 shares. Bessemer Group Inc stated it has 21 shares or 0% of all its holdings. Alpine Woods Cap Lc accumulated 0.02% or 3,284 shares. Verity Asset holds 0.26% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) or 2,891 shares. Jane Street Grp Limited Com accumulated 0% or 1,688 shares. Suntrust Banks reported 5,636 shares or 0% of all its holdings. Cortina Asset Mgmt Ltd Limited Liability Company invested in 0.34% or 67,026 shares.

Analysts await Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) to report earnings on February, 22. They expect $1.09 EPS, up 826.67% or $1.24 from last year’s $-0.15 per share. LGND’s profit will be $23.00M for 29.71 P/E if the $1.09 EPS becomes a reality. After $0.55 actual EPS reported by Ligand Pharmaceuticals Incorporated for the previous quarter, Wall Street now forecasts 98.18% EPS growth.

Investors sentiment decreased to 0.79 in Q2 2017. Its down 0.03, from 0.82 in 2017Q1. It is negative, as 85 investors sold GE shares while 816 reduced holdings. 111 funds opened positions while 598 raised stakes. 4.61 billion shares or 0.66% more from 4.58 billion shares in 2017Q1 were reported. Cap Planning Advsrs Ltd Liability invested in 106,724 shares. Ipswich Invest Mgmt Com Inc holds 207,761 shares. 147,673 were reported by Hayek Kallen Invest Management. Us Bankshares De reported 11.48 million shares or 1.03% of all its holdings. Umb Comml Bank N A Mo owns 444,989 shares or 0.42% of their US portfolio. Regal Inv Advsrs Llc holds 1.15% of its portfolio in General Electric Company (NYSE:GE) for 172,312 shares. Westport Asset has 0.98% invested in General Electric Company (NYSE:GE) for 42,178 shares. Carroll Fincl Assoc Inc holds 1.28% or 390,719 shares. Nine Masts Limited holds 13,291 shares. Horizon Lc invested in 29,244 shares or 0.05% of the stock. Sound Shore Mngmt Inc Ct has invested 2.85% in General Electric Company (NYSE:GE). Lafayette owns 17,775 shares or 0.18% of their US portfolio. 77,432 were accumulated by Bluemountain Cap Mgmt Lc. S&Co Incorporated reported 411,818 shares stake. Massachusetts Fin Svcs Co Ma, Massachusetts-based fund reported 1.32 million shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com